Clinical Trials

Do you have heart failure and need treatment with intravenous (IV) diuretics? This study is exploring the use of chloride supplementation in people with heart failure who require treatment with IV diuretics, which are used to help rid your body of excess water and salt. To participate in this study, you must have heart failure with signs of volume overload (rales, edema, elevated jugular venous pressure [JVP], or weight gain of at least 5 pounds) requiring treatment with IV diuretics. This study takes place in New Haven, Connecticut.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Have you been diagnosed with obstructive sleep apnea (OSA) and been referred to the Yale New Haven Hospital Sleep Center for continuous positive airway pressure (CPAP) treatment? This study is examining how the features that can raise or lower the risk of OSA can impact how well CPAP works in an individual. Researchers will use detailed sleep studies to determine which features contribute to OSA. Results from this study will help researchers develop treatment plans that can lead to personalized OSA treatments to improve patient lives. To participate in this study, you must be at least 19 years old. This study takes place in North Haven, Connecticut.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

The objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

Does your child have Down Syndrome? Did they have a complete atrioventricular septal defect (CAVSD) repair within the first year of their life? Researchers in this study are investigating how the
brain develops in children with Down Syndrome who have congenital heart disease. To participate, your child must be between 5 and 12 years old and have Down Syndrome. The study will enroll children who have congenital heart disease as well as children who do not have congenital heart disease. The study is taking place in locations in Delaware, Georgia, Indiana, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, South Carolina, Texas, Utah, Washington, D.C., and Toronto, Canada

Do you have severe asthma? Researchers in this study are trying to determine if a person's genetic makeup changes how a steroid used to treat asthma affects how well it works. You may be able to participate if you are between 18 and 50 years old. The study is taking place in Indianapolis, Indiana.

The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved.

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.